Sex steroids and bone: Current perspectives

Human Reproduction Update

Volumn 9, Issue 3, 2003, Pages 207-222

  Balasch, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bone homeostasis; Bone remodelling; Cytokines; Hormone replacement therapy; Osteoporosis; Ovarian steroids

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; DANAZOL; ESTROGEN DERIVATIVE; FLUORIDE; GESTAGEN; GONADORELIN AGONIST; GROWTH HORMONE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; NANDROLONE; NANDROLONE DERIVATIVE; NORETHISTERONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SOMATOMEDIN C; TAMOXIFEN; TESTOSTERONE; TIBOLONE; UNINDEXED DRUG;

ANOREXIA NERVOSA; APOPTOSIS; BONE MARROW; BONE MASS; BONE MINERAL; BREAST CANCER; CALCIUM BALANCE; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EARLY MENOPAUSE; EXERCISE; FEMALE; GONADAL DYSGENESIS; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERLIPOPROTEINEMIA; HYPERPROLACTINEMIA; HYSTERECTOMY; LACTATION; LIFESTYLE; LIVER DYSFUNCTION; MENARCHE; MENSTRUAL IRREGULARITY; NUTRITION; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SCOLIOSIS; VERTEBRA FRACTURE; VIRILIZATION;

BONE AND BONES; BONE DISEASES, METABOLIC; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; ORGAN SIZE; OSTEOPOROSIS; PREGNANCY; RISK FACTORS;

EID: 0038013575     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmg017     Document Type: Review

References (160)

1. Abdalla, H., Hart, D.M., Lindsay, R., Leggate, I. and Hooke, A. (1985) Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet. Gynecol., 66, 789-792.
2. Albright, F. (1947) The effect of hormones on osteogenesis in man. Rec. Prog. Horm. Res., 1, 293-353.
3. Albright, F. and Reifenstein, E.C., Jr (1947) Metabolic bone disease: osteoporosis. In: Albright, F. and Reifenstein, E.C. (eds), The Parathyroid Glands and Metabolic Bone Disease. Baltimore: Williams & Wilkins, pp. 145-204.
4. Albright, F., Bloomberg, F. and Smith, P.H. (1940) Postmenopausal osteoporosis. Trans. Assoc. Am. Phys., 55, 298-305.
5. American College of Physicians (1992) Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann. Intern. Med., 117, 1038-1041.
6. Bachmann, G.A. (2002) The hypoandrogenic woman: pathophysiologic overview. Fertil. Steril., 77 (Suppl. 4), S72-S76.
7. Bachmann, G.A., Bancroft, J., Braunstein, G., Burger, H., Davis, S., Dennerstein, L., Godstein, I., Guay, A., Leiblum, S., Lobo, R. et al. (2002) Female androgen insufficiency: the Princeton consensus statement on definition, classification and assessment. Fertil. Steril., 77, 660-665.
8. Bassey, E.J. (1995) Exercise in primary prevention of osteoporosis in women. Ann. Rheum. Dis., 54, 861-862.
9. Bilezikian, J.P. and Silverberg, S.J. (1992) Osteoporosis: a practical approach to the perimenopausal woman. J. Women's Res., 1, 21-27.
10. Breuil, V. and Euller-Ziegler, L. (2001) Gonadal dysgenesis and bone metabolism. Joint Bone Spine, 68, 26-33.
11. Burger, H.G. (2002a) Androgen production in women. Fertil. Steril., 77 (Suppl. 4), S3-S5.
12. Burger, H.G. (2002b) The role of androgen therapy. Best Pract. Res. Clin. Obstet. Gynecol., 16, 383-393.
13. Burkman, R.T., Collins, J.A. and Greene, R.A. (2001) Current perspectives on benefits and risks of hormone replacement therapy. Am. J. Obstet. Gynecol., 185 (Suppl. 2), S13-S23.
14. Bush, T.L. (1992) Feminine forever revisited: menopausal hormone therapy in the 1990s. J. Women's Health, 1, 1-14.
15. Castelo-Branco, C., Vicente, J.J., Figueras, F., Sanjuan, A., Martinez de Osaba, M.J., Casals, E., Pons, F., Balasch, J. and Vanrell, J.A. (2000) Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas, 34, 161-168.
16. Castelo-Branco, C., Gómez, O., Pons, F., Martinez de Osaba, M.J., Balasch, J. and Vanrell, J.A. (2003) Secreting ovarian tumors may protect women from osteoporosis. Gynecol. Oncol., 88, 149-152.
17. Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D. and Cummings, S.R. (1995) Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann. Intern. Med., 122, 9-16.
18. Cauley, J.A., Black, D.M., Barrett-Connor, E., Harris, F., Shields, K., Applegate, W. and Cummings, S.R. (2001) Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/progestin Replacement Study (HERS). Am. J. Med., 110, 442-450.
19. Christiansen, C. (1994) Hormone replacement therapy - standardized or individually adapted doses? - effect on bone mass. In: Berg, G. and Hammar, M. (eds), The Modern Management of the Menopause. The Parthenon Publishing Group, New York, pp. 337-341.
20. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet, 350, 1047-1059.
21. Compston, J.E. (1990) Osteoporosis. Clin. Endocrinol., 33, 653-682.
22. Compston, J.E. (1994) Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects. Reprod. Endocr. Rev., 3, 209-224.
23. Cooper, C., Hannaford, P., Croft, P. and Kay, C.R. (1993) Oral contraceptive pill use and fractures in women: a prospective study. Bone, 14, 41-45.
24. Cooper, G.S. and Thorp, J.M. (1999) FSH levels in relation to hysterectomy and to unilateral oophorectomy. Obstet. Gynecol., 94, 969-972.
25. Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Adachi, J., Wells, G., Shea, B., Guyatt, G., The Osteoporosis Methodology Group et al. (2002) Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev., 23, 524-528.
26. Cromer, B.A. (1999) Effects of hormonal contraceptives on bone mineral density. Drug Safety, 20, 213-222.
27. Crosignani, P.G. and Vegetti, W. (1996) A practical guide to the diagnosis and management of amenorrhea. Drugs, 52, 671-681.
28. Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barret-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C. et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280, 2077-2082.
29. Cundy, T., Evans, M., Roberts, H., Wattie, D., Ames, R. and Reid, I.R. (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br. Med. J., 303, 13-16.
30. Cundy, T., Farquhar, C.M., Cornish, J. and Reid, I.R. (1996) Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J. Clin. Endocrinol. Metab., 81, 1014-1017.
31. Dawood, M.Y. (1994) Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet. Gynecol. Scand., 159, 22-34.
32. Dayal, M. and Barnhart, K.T. (2001) Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin. Reprod. Med., 19, 295-303.
33. Deary, A.J., Breeze, A.C.G., Barlow, D. and Prentice, A. (2002) Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density (Cochrane Review). In: The Cochrane Library, Issue 1, 2002.
34. DeCherney, A. (1993) Physiologic and pharmacologic effects of estrogen and progestins on bone. J. Reprod. Med., 38, (Suppl.), 1007-1014.
35. Delmas, P.D. (1995) Biochemical markers for the assessment of bone turnover. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 319-333.
36. DeSouza, M.J., Miller, B.E., Sequenzia, L.C., Luciano, A.A., Ulreich, S., Stier, S., Prestwood, K. and Lesley, B.L. (1997) Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J. Clin. Endocrinol. Metab., 82, 2867-2876.
37. Dimitrakakis, C., Zhou, J. and Bondy, C.A. (2002) Androgens and mammary growth and neoplasia. Fertil. Steril., 77, (Suppl. 4), S26-S33.
38. Dixon, J.M. (2001) Hormone replacement therapy and the breast: we should worry about the increase in the risk of breast cancer. Br. Med. J., 323, 1381-1382.
39. Dorgan, J.F., Boudou, P., Stanczyk, F.Z., Longcope, C., Tejpar, E.A., Falk, R.T., Schussler, N. and Stephenson, H.E., Jr (2001) Sources of elevated serum androgens in postmenopausal women who develop breast cancer. Cancer Epidemiol. Biomarkers Prev., 10, 407-410.
40. Drinkwater, B.L., Nilson, K., Ott, S. and Chesnut, C.H., III (1986) Bone mineral density after resumption of menses in amenorrheic athletes. JAMA, 256, 380-382.
41. Edmonds, D.K. (1996) Add-back therapy in the treatment of endometriosis: the European experience. Br. J. Obstet. Gynecol., 103 (Suppl. 14), 10-13.
42. Eldred, J.M., Haynes, P.J. and Thomas, E.J. (1992) A randomized double-blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin. Endocrinol. (Oxf.), 37, 354-359.
43. Ensrud, K.E., Palermo, L., Black, D.M., Cauley, J., Jergas, M., Orwoll, E.S., Nevitt, M.C., Fox, K.M. and Cummings, S.R. (1995) Hip and calcaneal bone loss increase with advancing age: longitudinal results from the Study of Osteoporotic Fractures. J. Bone Miner. Res., 10, 1778-1787.
44. Eriksen, E.F., Colvard, D.S., Berg, N.J., Graham, M.L., Mann, K.G., Spelsberg, T.C. and Riggs, B.L. (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science, 241, 84-86.
45. Felson, D.T., Zhang, Y., Hanna, M.T., Kiel, D.P., Wilson, P.W. and Anderson, J.J. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med., 329, 1141-1146.
46. Friedrich, M.J. (2001) Recent studies bring risks, benefits of hormone replacement therapy under scrutiny. J. Natl Cancer Inst., 93, 1287-1288.
47. Fujimura, R., Ashizawa, N., Watanabe, M., Mukai, N., Amagai, H., Fukubayashi, T., Hayashi, K., Tokuyama, K. and Suzuki, M. (1997) Effect of resistance exercise training on bone formation and resorption in young male subjects assessed by biomarker of bone metabolism. J. Bone Miner. Res. 12, 656-662.
48. Gallagher, J.C., Kabel, W.T. and Goldgar, D. (1991) Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am. J. Med., 90, 171-178.
49. Grady, D. and Cummings, S.R. (2001) Postmenopausal hormone therapy for prevention of fractures: how good is the evidence? JAMA, 285, 2909-2910.
50. Grady, D., Rubin, S.M., Petiti, D.B., Fox, C.S., Black, D., Ettinger, B., Ernster, V.L. and Cummings, S.R. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med., 117, 1016-1037.
51. Gregoriou, O., Kouskouni, E., Bakas, P., Konidaris, S., Papadias, K., Kalovidouris, A. and Creatsas, G. (2000) Bone mineral density in women with idiopathic hirsutism. Gynecol. Endocrinol., 14, 364-368.
52. Hankinson, S.E., Hunter, D.J., Colditz, G.A., Willett, W.C., Stampfer, M.J., Rosner, B., Hennekens, C.H. and Speizer, F.E. (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA, 270, 2813-2818.
53. Hartard, M., Bottermann, P., Bartenstein, P., Jeschke, D. and Schwaiger, M. (1997) Effects on bone mineral density of low-dose oral contraceptives compared to and combined with physical activity. Contraception, 55, 87-90.
54. Heaney, R.P. (1987) The role of nutrition in prevention and management of osteoporosis. Clin. Obstet. Gynecol., 30, 833-846.
55. Hemminki, E. and Sihvo, S. (1993) A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet. Gynecol., 82, 1021-1028.
56. Herrington, D.M. (1999) The HERS trial results: paradigms lost? Ann. Intern. Med., 131, 463-466.
57. Hornstein, M.D. and Barbieri, R.L. (1988) Endocrine therapy of endometriosis: Danazol and the synthetic progestins. In: Barbieri, R.L. and Schiff, I. (eds), Reproductive Endocrine Therapeutics. Alan R. Liss, Inc., New York, pp. 155-185.
58. Horowitz, M., Wishart, J.M., Need, A.G., Morris, H.A. and Nordin, B.E. (1993) Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Clin. Endocrinol., 39, 649-655.
59. Hreshchyshyn, M.M., Hopkins, A., Zylstra, S. and Anbar, M. (1988) Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities. Obstet. Gynecol., 72, 631-638.
60. Hulka, B.S. (1994) Links between hormone replacement therapy and neoplasia. Fertil. Steril., 62 (Suppl. 2), 168S-175S.
61. Hulka, B.S. and Stark, A.T. (1995) Breast cancer: cause and prevention. Lancet, 346, 883-887.
62. Hulley, S., Furberg, C., Barret-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunninghake, D. for the HERS Research Group (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA, 288, 58-66.
63. Humphrey L.L., Chan, B.K.S. and Sox, H.C. (2002) Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann. Intern. Med., 137, 273-284.
64. Ishida, Y. and Heersche, J.N.M. (1999) Progesterone- and dexamethasone-dependent osteoprogenitors in bone cell populations derived from rat vertebrae are different and distinct. Endocrinology, 140, 3210-3218.
65. Ishida, Y. and Heersche, J.N.M. (2002) Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos. Int., 13, 601-605.
66. Jeng, M.H., Parker, J. and Jordan, C. (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res., 52, 6539-6546.
67. Johnston, C.C. and Melton, L.J., III (1995) Bone densitometry. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 275-297.
68. Jordan, V.C. (2001) The past, present, and future of selective estrogen receptor modulation. Ann. N. Y. Acad. Sci., 949, 72-79.
69. Jordan, V.C., Jeng, M.H., Catherino, W.H. and Parker, C.J. (1993) The estrogenic activity of synthetic progestin used in oral contraceptives. Cancer, 71, 1501-1505.
70. Jordan, V.C., Gapstur, S. and Morrow, M. (2001) Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl Cancer. Inst., 93, 1449-1457.
71. Kaunitz, A.M. (1998) Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int. J. Fertil. Womens Med., 43, 73-83.
72. Kaunitz, A.M. (2002) Current concepts regarding use of DMPA. J. Reprod. Med., 47, (Suppl. 9), 785-789.
73. Khosla, S.K., Riggs, B.L. and Melton, L.J., III (1995) Clinical spectrum. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 205-223.
74. Kiesel, L., Schweppe, K.W., Sillem, M. and Siebzehnrübl, E. (1996) Should add-back therapy for endometriosis be deferred for optimal results? Br. J. Obstet. Gynecol., 103 (Suppl. 14), 15-17.
75. Komm, B.S., Terpening, C.M., Benz, N.J., Graeme, K.A., Gallegos, A., Korc, M., Greene, G.L., O'Malley, B.W. and Haussler, M.R. (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science, 241, 81-84.
76. Kousteni, S., Bellido, T., Plotkin, L.I., O'Brien, C.A., Bodenner, D.L., Han, L., Han, K., DiGregorio, G.B., Katzenellenbogen, J.A., Katzenellenbogen, B.S. et al. (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell, 104, 719-730.
77. Lacey, J.V., Jr, Mink, P.J., Lubin, J.H., Sherman, M.E., Troisi, R., Hartge, P., Schtzkin, A. and Schrairer, C. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA, 288, 334-341.
78. Laine, C. (2002) Postmenopausal hormone replacement therapy: how could we have been so wrong? Ann. Intern. Med., 137, 290.
79. Liao, D.J. and Dickson, R.B. (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J. Steroid Biochem. Mol. Biol., 80, 175-189.
80. Lindsay, R. (1987) The menopause: sex steroids and osteoporosis. Clin. Obstet. Gynecol., 30, 847-859.
81. Lindsay, R. (1995) Estrogen deficiency. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 133-160.
82. Lobo, R.A. and Speroff, L. (1994) International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil. Steril., 61, 592-595.
83. Luukkainen, T., Pakarinen, P. and Toivonen, J. (2001) Progestin-releasing intrauterine systems. Semin. Reprod. Med., 19, 355-363.
84. Mais, V., Fruzzetti, F., Aiossa, S., Paoletti, A.M., Guerriero, S. and Melis, G.B. (1993) Bone metabolism in young women taking a monophasic pill containing 20 μg ethinylestradiol. Contraception, 48, 445-452.
85. Manolagas, S.C. (1999) Cell number versus cell vigor - what really matters to a regenerating skeleton? Endocrinology, 140, 4377-4381.
86. Manolagas, S.C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 21, 115-137.
87. Manolagas, S.C., Kousteni, S. and Jilka, R.L. (2002) Sex steroids and bone. Recent Prog. Horm. Res., 57, 385-409.
88. Marcus, R. (2002) Post-menopausal osteoporosis. Best Pract. Res. Clin. Obstet. Gynecol., 16, 309-327.
89. Marcus, R., Cann, C. and Madvig, D. (1985) Menstrual function and bone mass in elite women distance runners. Ann. Intern. Med., 102, 158-163.
90. McClung, M.R., Geusens, P. and Miller, P.D. (2001) Effect of risedronate on the risk of hip fracture in elderly women: HIP Intervention Program. N. Engl. J. Med., 344, 333-340.
91. McNagny, S.E. and Wenger, N.K. (2002) Postmenopausal hormone-replacement therapy. N. Engl. J. Med., 346, 63.
92. Meckstroth, K.R. and Darney, P.D. (2001) Implant contraception. Semin. Reprod. Med., 19, 339-354.
93. Michaëlsson, K., Baron, J.A., Farahmand, B.Y., Persson, I. and Ljunghall, S. (1999) Oral contraceptive use and risk of hip fracture: a case-control study. Lancet, 353, 1481-1484.
94. Moghissi, K.S. (1996) Add-back therapy in the treatment of endometriosis: the North American experience. Br. J. Obstet. Gynecol., 103 (Suppl. 14), 14.
95. Narod, S.A., Sun, P., Ghadirian, P., Lynch, H., Isaacs, C., Garber, J., Weber, B., Karlan, B., Fishman, D., Rosen, B. et al. (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet, 357, 1467-1470.
96. Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 344, 1434-1441.
97. Nelson, H.D., Rizzo, J., Harris, E., Cauley, J., Ensrud, K., Bauer, D.C., Orwoll, E.: Study of Osteoporotic Fractures Research Group (2002a) Osteoporosis and fractures in postmenopausal women using estrogen. Arch. Intern. Med., 162, 2278-2284.
98. Nelson, H.D., Humphrey, L.L., Nygren, P., Teutsch, S.M. and Allan, J.D. (2002b) Postmenopausal hormone replacement therapy. Scientific review. JAMA, 288, 872-881.
99. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA, 285, 785-795.
100. Noller, K.L. (2002) Estrogen replacement therapy and risk of ovarian cancer. JAMA, 288, 368-369.
101. Nordin, B.E., Need, A.G., Chatterton, B.E., Horowitz, M. and Morris, H.A. (1990) The relative contributions of age and years since menopause to postmenopausal bone loss. J. Clin. Endocrinol. Metab., 70, 83-88.
102. Notelovitz, M. (1988) The non-hormonal management of menopause. In: Studd, J.W.W. and Whitehead, M.I. (eds), The Menopause. Blackwell Scientific Publications, Oxford, pp. 102-115.
103. Notelovitz, M. (1993) Osteoporosis: screening, prevention, and management. Fertil. Steril., 59, 707-725.
104. Notelovitz, M. (2002a) Androgen effects on bone and muscle. Fertil. Steril., 77 (Suppl. 4), S34-S41.
105. Notelovitz, M. (2002b) Overview of bone mineral density in postmenopausal women. J. Reprod. Med., 47 (Suppl. 1), 71-81.
106. Orwoll, E.S. and Nelson, H.D. (1999) Does estrogen adequately protect postmenopausal women against osteoporosis: an iconoclastic perspective. J. Clin. Endocrinol. Metab., 84, 1872-1874.
107. Orwoll, E.S., Yuzpe, A.A., Burry, K.A., Heinrichs, L., Buttram, V.C. and Hornstein, M.D. (1994) Nafarelin therapy in endometriosis: long-term effects on bone mineral density. Am. J. Obstet. Gynecol., 171, 1221-1225.
108. Paoletti, A.M., Serra, G.G., Cagnacci, A., Vacca, A.M., Guerreiro, S., Solla, E. and Melis, G.B. (1996) Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analogue treatment. Fertil. Steril., 65, 707-710.
109. Parfitt, A.M. (1987) Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin. Obstet. Gynecol., 30, 789-811.
110. Pike, M.C. and Spicer, D.V. (2000) Hormonal contraception and chemoprevention of female cancers. Endocr. Relat. Cancer, 7, 73-83.
111. Pinkerton, J.V. and Santen, R. (2002) Use of alternatives to estrogen for treatment of menopause. Minerva Endocrinol., 27, 21-41.
112. Prior, J.C. (1990) Progesterone as a bone-trophic hormone. Endocr. Rev., 11, 386-398.
113. Prior, J.C., Vigna, Y.M., Barr, S.I., Rexworthy, C. and Lentle, B.C. (1994) Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbance. Am. J. Med., 96, 521-530.
114. Raisz, L.G., Wiita, B., Artis, A., Bowen, A., Schwartz, S., Trahiotis, M., Shoukri, K. and Smith, J. (1996) Comparison of the effects of estrogen alone plus and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J. Clin. Endocrinol. Metab., 81, 37-43
115. Randall, T. (1993) Women need more and better information on menopause from their physicians. JAMA, 270, 1664.
116. Reeve, J. (2000) How do women develop fragile bones? J. Steroid Biochem. Mol. Biol., 74, 375-381.
117. Reginster, J.Y., Bruyere, O., Audran, M., Avouac, B., Body, J.J., Bouvenot, G., Brandi, M.L., Gennari, C., Kaufman, J.M., Lemmel, E.M., Vanhaelst, L., Weryha, G., Devogelaer, J.P., On behalf of the Group for the Respect of Ethics and Excellence in Science (GREES) (2000) Do estrogens effectively prevent osteoporosis-related fractures? Calcif. Tissue Int., 67, 191-194.
118. Rekers, H. (1991) Mastering the menopause. In: Burger, H. and Boulet, M. (eds), A Portrait of the Menopause. The Parthenon Publishing Group, Carnforth, Lancs, UK, pp. 23-43.
119. Riggs, B.L. and Khosla, S. (1995) Practical clinical management. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 487-502.
120. Riggs, B.L., Khosla, S. and Melton, J., III (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev., 23, 279-302.
121. Riis, B.J., Christiansen, C., Johansen, J.S. and Jacobson, J. (1990) Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J. Clin. Endocrinol. Metab., 70, 920-924.
122. Riman, T., Dickman, P.W., Nilsson, S., Correia, N., Nordlinder, H., Magnusson, C.M., Weiderpass, E. and Persson, I.R. (2002a) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl Cancer Inst., 94, 497-504.
123. Riman, T., Dickman, P.W., Nilsson, S., Correia, N., Nordlinder, H., Magnusson, C.M. and Persson, I.R. (2002b) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am. J. Epidemiol., 156, 363-373.
124. Rodan, G.A. and Rodan, S.B. (1995) The cells of bone. In: Riggs, B.L. and Melton, L.J., III (eds), Osteoporosis: Etiology, Diagnosis, and Management, 2nd edition. Lippincott-Raven Publishers, Philadelphia, pp. 1-39.
125. Rodriguez, C., Patel, A.V., Calle, E.E., Jacob, E.J. and Thun, M.J. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA, 285, 1460-1465.
126. Rosen, C.J. and Bilezikian, J.P. (2001) Anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab., 86, 957-964.
127. Rosen, H.N. and Rosenblatt, M. (2002) Epidemiology and causes of osteoporosis. UpToDate, February 25, 2002.
128. Rosenberg, L. (1993) Hormone replacement therapy: the need for reconsideration. Am. J. Public Health, 83, 1670-1673.
129. Rosenblatt, K.A., Thomas, D.B. and The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1996) Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol. Biomarkers Prev., 5, 933-935.
130. Sarrel, P.M. (2002) Androgen deficiency: menopause and estrogen-related factors. Fertil. Steril., 77 (Suppl. 4), S63-S67.
131. Schlechte, J.A., Sherman, B. and Martin, B. (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab., 56, 1120-1123.
132. Schot, L.P.C. and Schuurs, A.H.W.M. (1990) Sex steroids and osteoporosis: effects of deficiencies and substitutive treatments. J. Steroid Biochem. Mol. Biol., 37, 167-182.
133. Siddle, N., Sarrel, P. and Whitehead, M. (1987) The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril., 47, 94-100.
134. Simon, J.A. (2001) Safety of estrogen/androgen regimens. J. Reprod. Med., 46 (3 Suppl.), 281-290.
135. Simon, J.A. (2002) Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil. Steril., 77 (Suppl. 4), S77-S82.
136. Simon, J.A., Hunninghake, D.B., Agarwal, S.K., Lin, F., Cauley, J.A., Ireland, C.C. and Pickar, J.H. (2001) Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med., 135, 493-501.
137. Slayden, S.M. (1998) Risks of menopausal androgen supplementation. Semin. Reprod. Endocrinol., 16, 145-152.
138. Slemenda, C., Longcope, C., Peacock, M., Hui, S. and Johnston, C.C. (1996) Sex steroids, bone mass, and bone loss: a prospective study of pre-, peri-, and post-menopausal women. J. Clin. Invest., 97, 14-21.
139. Slootweg, M.C., Ederveen, A.G.H., Schot, L.P.C., Schoonen, W.G.E.J. and Kloosterboer, H.J. (1992) Oestrogen and progestogen synergistically stimulate human and rat osteoblast proliferation. J. Endocrinol., 133, R5-R8.
140. Souza, A.Z., Fonseca, A.M., Izzo, V.M., Clauzet, R.M. and Salvatore, C.A. (1986) Ovarian histology and function after total abdominal hysterectomy. Obstet. Gynecol., 68, 847-849.
141. Sowers, M.F.R. and Galuska, D.A. (1993) Epidemiology of bone mass in premenopausal women. Epidemiol. Rev., 15, 374-398.
142. Sowers, M., Clark, M.K., Hollis, B., Wallace, R.B. and Jannausch, M. (1992) Radial bone mineral density in pre- and perimenopausal women: a prospective study of rates and risk factors of loss. J. Bone Miner. Res., 7, 647-657.
143. Sowers, M., Randolph, J.F., Crutchfield, M., Jannausch, M.L., Shapiro, B., Zhang, B. and LaPietra, M. (1998) Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J. Bone Miner. Res., 13, 1191-1202.
144. Speroff, L., Rowan, J., Symons, J., Genant, H. and Wilborn, W. (1996) The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (Chart Study). JAMA, 276, 1397-1403.
145. Speroff, L., Glass, R.H. and Kase, N.G. (1999) Clinical Gynecological Endocrinology and Infertility. 6th edition. Lippincott Williams & Wilkins, Baltimore.
146. Spicer, D.V., Pike, M.C., Pike, A., Rude, R., Shoupe, D. and Richardson, J. (1993) Pilot trial of a gonadotropin releasing hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception, 47, 427-444.
147. Stampfer, M.J. and Hankinson, S.E. (1997) Estrogen and breast cancer: the duration connection. Menopause, 4, 123-124.
148. Stevenson, J.C. (1990) Pathogenesis, prevention, and treatment of osteoporosis. Obstet. Gynecol., 75, 36S-41S.
149. Studd, J. and Leather, A.T. (1996) The need for add-back with gonadotrophin-releasing hormone agonist therapy. Br. J. Obstet. Gynecol., 103 (Suppl. 14), 1-4.
150. Sugimoto, A.K., Hodsman, A.B. and Nisker, J.A. (1993) Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil. Steril., 60, 672-674.
151. The Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density. Results from the post-menopausal estrogen/progesterone intervention (PEPI) trial. JAMA, 276, 1389-1396.
152. Tudor-Locke, C. and McColl, R.S. (2000) Factors related to variation in premenopausal bone mineral status: a health promotion approach. Osteoporos. Int., 11, 1-24.
153. Vastag, B. (2002) Hormone replacement therapy falls out of favor with expert committee. JAMA, 287, 1923-1924.
154. Vessey, M., Mant, J. and Painter, R. (1998) Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception, 57, 231-235.
155. Waller, K., Reim, J., Fenster, L., Swan, S.H., Brumback, B., Windham, G.C., Lasley, B., Ettinger, B. and Marcus, R. (1996). Bone mass and subtle abnormalities in ovulatory function in healthy women. J. Clin. Endocrinol. Metab., 81, 663-668.
156. Wang, L. and Arnold, K. (2002) Hormone replacement therapy may be associated with increased ovarian cancer risk. J. Natl Cancer Inst., 94, 467.
157. Warren, M.P., Brooks-Gunn, J., Hamilton, L.H., Warrent, L.J. and Hamilton, W.G. (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight-bearing bones. J. Clin. Endocrinol. Metab., 72, 847-853.
158. Wei, L.L., Leach, M.N., Miner, R.S. and Demers, L.M. (1993) Evidence for progesterone receptors in human osteoblast-like cells. Biochem. Biophys. Res. Commun., 195, 525-532.
159. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288, 321-333.
160. Zborowski, J.V., Cauley, J.A., Talbott, E.O., Guzick, D.S. and Winters, S.J. (2000) Bone mineral density, androgens and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. J. Clin. Endocrinol. Metab., 67, 937-943.